Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma
- First Posted Date
- 2015-08-20
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Air Force Military Medical University, China
- Target Recruit Count
- 330
- Registration Number
- NCT02529761
- Locations
- 🇨🇳
Xijing Hospital of digestive disease, Fourth Military Medical University, Xi'an, Shaanxi, China
Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02504983
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Taoyuan, Taiwan
Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML
- Conditions
- Interventions
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 202
- Registration Number
- NCT02474290
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT02460991
- Locations
- 🇺🇸
University of Alabama Hospital, Birmingham, Alabama, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02450149
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, seoul, korea, Republic of, Korea, Republic of
Adjuvant Therapies for Patients With HCC and MVI
- Conditions
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 240
- Registration Number
- NCT02436902
- Locations
- 🇨🇳
Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning, Guangxi, China
Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 47
- Registration Number
- NCT02425605
- Locations
- 🇰🇷
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
- Conditions
- Interventions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- e-Therapeutics PLC
- Target Recruit Count
- 112
- Registration Number
- NCT02423239
- Locations
- 🇩🇪
University Hospital Bonn, Study Center Bonn (SZB) Clinical Study Core Unit Institute of Clinical Chemistry and Clinical Pharmacology University Hospital Bonn, Sigmund-Freud-Str. 25, Bonn, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf II. Medizinischen Klinik Martinistr. 52, Hamburg, Germany
🇩🇪Klinikum der Ruhr-Universitaet Bochum, Medizinische Klinik III - Hämatologie/Onkologie Marien Hospital Herne Universitätsklinikum der Ruhr-Universität Bochum Hölkeskampring 40, Herne, Germany
Epigenetic Reprogramming in Relapse AML
- Conditions
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Michael Burke
- Target Recruit Count
- 3
- Registration Number
- NCT02412475
- Locations
- 🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Delcath Systems Inc.
- Registration Number
- NCT02406508
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States
🇺🇸Montefiore Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.